Suresh Vazirani–led Transasia Bio-Medicals Ltd, which provides solutions for clinical diagnosis, has acquired Turkish firm Diasis Diagnostic Systems, an in vitro diagnostics player, for an undisclosed amount.
The acquisition has been done through Transasia’s wholly owned German subsidiary ERBA Diagnostics Mannheim, GmbH [Erba]. Following the acquisition, Suresh Vazirani, the Founder Chairman of Erba-Transasia Group has become the Chairman of Diasis Diagnostic Systems.
This is the third international acquisition by Erba Diagnostics Mannheim GmbH in a span of 16 months. It recently acquired Czech Republic-based IVD company Lachema with its subsidiary in Russia. This was followed by the acquisition of an American IVD company, IVAX Diagnostics Inc having two subsidiaries in the U.S. and one in Italy.
With these two strategic acquisitions, Erba-Transasia Group now has a direct corporate presence in the US, Italy, Czech Republic, Russia, Germany and India. The Group already has its presence in over 50 countries through its distribution and marketing network.
Diasis Diagnostic Systems, established in 1993 is involved in the development, production and marketing of products for In Vitro Diagnostics in the field of biochemistry, haematology and urine analysis.